Genmab — December 2015
-
ASH-studier vidner om øget konkurrence for Genmab-midler
En række medicinalselskaber har præsenteret nye data for sine respektive kræftmidler inden for Genmabs to vigtigste kræftindikationer, og de vidner om fornyet konkurrence for det danske biotekselskab.
(medwatch.dk)
-
5 minutter så går det løs. Find popcornene frem
-
var det 13.15 Lithium?
-
13:30 dansk tid
-
GEN503 13:30
-
Okay hvad med Pomalyst?
-
Dara/Pom/Dex 13:45
-
Perfekt tak. Troede lige det var 13.00 og 13.15 - kunne heller ikke forstå vi ikke havde hørt noget
-
Tager det kun 15 min hver? eller overlapper de hinanden?
-
Det er 2 forskellige speakers (Torben og en Ajai Chari) så går ud fra at det blot bliver 2 hurtige præsentationer af resultaterne
-
-
-
Genmab er hurtige: De har lagt hele præsentationen op nu: http://files.shareholder.com/downloads/AMDA-KPIBN/961210947x0x864981/A4C55FC0-9A6D-4054-994A-E55638CEA4A0/Plesner_GEN503_Presentation_ASH2015_12-6-15.pdf
-
Så er det Pomalyst tid
-
Response rates with Dara Len dex 88% -suggests use of dex and fears of abrogating immune effects of Dara are not real #ASH15 #mmsm #immunonc
-
-
Svært at nå at følge med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind